Cytosorbents Corporation
CTSO
$1.11
-$0.05-4.31%
NASDAQ
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | 6.52M | 9.39M | 9.89M | 9.79M | 3.40M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 6.52M | 9.39M | 9.89M | 9.79M | 3.40M |
| Cost of Revenue | -247.90K | 4.11M | 3.39M | 3.22M | -1.47M |
| Gross Profit | 6.77M | 5.28M | 6.50M | 6.57M | 4.87M |
| SG&A Expenses | 9.83M | 7.76M | 8.22M | 9.25M | 11.47M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 10.88M | 13.72M | 13.13M | 14.71M | 13.96M |
| Operating Income | -4.36M | -4.33M | -3.23M | -4.93M | -10.56M |
| Income Before Tax | -9.57M | -2.33M | -4.14M | -6.36M | -7.39M |
| Income Tax Expenses | -1.69M | -- | -- | -- | -813.70K |
| Earnings from Continuing Operations | -7.88M | -2.33M | -4.14M | -6.36M | -6.57M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -7.88M | -2.33M | -4.14M | -6.36M | -6.57M |
| EBIT | -4.36M | -4.33M | -3.23M | -4.93M | -10.56M |
| EBITDA | -3.97M | -3.95M | -2.83M | -4.53M | -10.17M |
| EPS Basic | -0.14 | -0.04 | -0.08 | -0.12 | -0.14 |
| Normalized Basic EPS | -0.11 | -0.03 | -0.05 | -0.07 | -0.11 |
| EPS Diluted | -0.14 | -0.04 | -0.08 | -0.12 | -0.14 |
| Normalized Diluted EPS | -0.11 | -0.03 | -0.05 | -0.07 | -0.11 |
| Average Basic Shares Outstanding | 54.71M | 54.45M | 54.31M | 54.26M | 46.55M |
| Average Diluted Shares Outstanding | 54.71M | 54.45M | 54.31M | 54.26M | 46.55M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |